Costs, effects and C/E-ratios alongside a clinical trial

Health Econ. Sep-Oct 1994;3(5):309-19. doi: 10.1002/hec.4730030505.

Abstract

A general approach is discussed to assess the uncertainty surrounding the cost effectiveness ratio (C/E-ratio) estimated on the basis of data from a randomised clinical trial. The approach includes the calculation of a 95% probability ellipse and introduces the concept of a so called C/E-acceptability curve. This last curve defines for each predefined C/E-ratio the probability that the C/E-ratio found in the study is acceptable. The approach is illustrated by estimates of costs per life saved and costs per patient discharged alive on the basis of data from a phase II trial addressing the value of anakinra in treating sepsis syndrome.

MeSH terms

  • Cost-Benefit Analysis*
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Models, Economic
  • Randomized Controlled Trials as Topic / economics*
  • Sialoglycoproteins / economics
  • Sialoglycoproteins / therapeutic use
  • Systemic Inflammatory Response Syndrome / drug therapy
  • Systemic Inflammatory Response Syndrome / economics
  • Value of Life

Substances

  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Sialoglycoproteins